Health
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet
Taking safety, immunogenicity, and production capacity into account, the 3 μg doseof CoronaVac is the suggested dose for efficacy assessment in future phase 3 trials….
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions
-
General22 hours agoWondering about winter | The Spectator Australia
-
Noosa News20 hours agoJane Bunn weather: Cyclone Errol forms as effects of Alfred still felt across Queensland
-
Business23 hours agoWiseTech shares lift off amid agreement with founder Richard White
-
Noosa News18 hours agoThis 42-Kilometre Walking Trail on the NSW North Coast Weaves Through Ancient Rainforest, Volcanic Mountains and Spectacular Waterfalls